Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial

Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The footer’s site revision number was updated from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T01:41:00.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.0 to v3.7.1.
    Difference
    0.3%
    Check dated 2026-10-11T02:05:56.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    A vertical Feedback tab appears along the right edge of the page, while the study record continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-04T01:58:29.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error page with a small header, a Home link, and a site revision tag (Revision: v3.7.0). This indicates an access restriction rather than the expected study record details.
    Difference
    20%
    Check dated 2026-09-20T00:51:02.000Z thumbnail image
  5. Check
    50 days ago
    Change Detected
    Summary
    The page revision label was updated from v3.6.5 to v3.6.6. This reflects a deployment of updates to the page template or metadata without changes to the study data.
    Difference
    0.1%
    Check dated 2026-08-29T21:43:09.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.4 to v3.6.5, indicating a minor update to the page template. This does not appear to modify any study details or eligibility information.
    Difference
    0.1%
    Check dated 2026-08-08T20:34:24.000Z thumbnail image

Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.